STOCK TITAN

[Form 4] BeOne Medicines Ltd. American Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

BeOne Medicines (ONC) filed a routine Form 4 showing Global Head of R&D Lai Wang sold 1,028 American Depositary Shares on 06/23/2025 at $260 each (≈ $0.27 million) to cover tax withholding linked to vested RSUs. After the sale, he still holds 1,023,529 ordinary shares directly and 731,965 indirectly via Wang Holdings LLC—together ≈ 1.76 million shares. The transaction represents under 1 % of his total ownership and is not considered material.

BeOne Medicines (ONC) ha presentato una routine Modulo 4 che mostra che il Responsabile Globale della Ricerca e Sviluppo Lai Wang ha venduto 1.028 American Depositary Shares il 23/06/2025 a 260$ ciascuna (circa 0,27 milioni di dollari) per coprire le tasse trattenute relative alle RSU maturate. Dopo la vendita, detiene ancora 1.023.529 azioni ordinarie direttamente e 731.965 indirettamente tramite Wang Holdings LLC—per un totale di circa 1,76 milioni di azioni. La transazione rappresenta meno dell'1% del suo totale posseduto e non è considerata significativa.

BeOne Medicines (ONC) presentó un Formulario 4 rutinario que muestra que el Jefe Global de I+D, Lai Wang, vendió 1.028 American Depositary Shares el 23/06/2025 a $260 cada una (aproximadamente $0.27 millones) para cubrir la retención de impuestos relacionada con RSU adquiridas. Después de la venta, aún posee 1.023.529 acciones ordinarias directamente y 731.965 indirectamente a través de Wang Holdings LLC—un total aproximado de 1.76 millones de acciones. La transacción representa menos del 1% de su propiedad total y no se considera material.

BeOne Medicines (ONC)는 글로벌 연구개발 책임자 Lai Wang2025년 6월 23일1,028주의 미국예탁증서(ADS)를 주당 260달러에 매도하여 약 27만 달러의 세금 원천징수분을 충당했다고 정기 Form 4를 제출했습니다. 매도 후 그는 직접 1,023,529주와 Wang Holdings LLC를 통해 간접적으로 731,965주를 보유하고 있어 총 약 176만 주를 보유 중입니다. 이 거래는 전체 보유 지분의 1% 미만으로, 중요 거래로 간주되지 않습니다.

BeOne Medicines (ONC) a déposé un formulaire 4 de routine indiquant que le responsable mondial de la R&D, Lai Wang, a vendu 1 028 American Depositary Shares le 23/06/2025 au prix de 260 $ chacune (environ 0,27 million de dollars) pour couvrir la retenue d'impôt liée aux RSU acquises. Après la vente, il détient encore 1 023 529 actions ordinaires directement et 731 965 indirectement via Wang Holdings LLC, soit environ 1,76 million d’actions au total. La transaction représente moins de 1 % de sa détention totale et n’est pas considérée comme significative.

BeOne Medicines (ONC) reichte ein routinemäßiges Formular 4 ein, das zeigt, dass der globale Leiter der Forschung & Entwicklung, Lai Wang, am 23.06.2025 1.028 American Depositary Shares zu je 260 USD (ca. 0,27 Millionen USD) verkauft hat, um die Steuerabzüge im Zusammenhang mit erworbenen RSUs zu decken. Nach dem Verkauf hält er noch 1.023.529 Stammaktien direkt und 731.965 indirekt über Wang Holdings LLC – zusammen etwa 1,76 Millionen Aktien. Die Transaktion macht weniger als 1 % seines Gesamtbesitzes aus und wird nicht als wesentlich betrachtet.

Positive
  • None.
Negative
  • None.

BeOne Medicines (ONC) ha presentato una routine Modulo 4 che mostra che il Responsabile Globale della Ricerca e Sviluppo Lai Wang ha venduto 1.028 American Depositary Shares il 23/06/2025 a 260$ ciascuna (circa 0,27 milioni di dollari) per coprire le tasse trattenute relative alle RSU maturate. Dopo la vendita, detiene ancora 1.023.529 azioni ordinarie direttamente e 731.965 indirettamente tramite Wang Holdings LLC—per un totale di circa 1,76 milioni di azioni. La transazione rappresenta meno dell'1% del suo totale posseduto e non è considerata significativa.

BeOne Medicines (ONC) presentó un Formulario 4 rutinario que muestra que el Jefe Global de I+D, Lai Wang, vendió 1.028 American Depositary Shares el 23/06/2025 a $260 cada una (aproximadamente $0.27 millones) para cubrir la retención de impuestos relacionada con RSU adquiridas. Después de la venta, aún posee 1.023.529 acciones ordinarias directamente y 731.965 indirectamente a través de Wang Holdings LLC—un total aproximado de 1.76 millones de acciones. La transacción representa menos del 1% de su propiedad total y no se considera material.

BeOne Medicines (ONC)는 글로벌 연구개발 책임자 Lai Wang2025년 6월 23일1,028주의 미국예탁증서(ADS)를 주당 260달러에 매도하여 약 27만 달러의 세금 원천징수분을 충당했다고 정기 Form 4를 제출했습니다. 매도 후 그는 직접 1,023,529주와 Wang Holdings LLC를 통해 간접적으로 731,965주를 보유하고 있어 총 약 176만 주를 보유 중입니다. 이 거래는 전체 보유 지분의 1% 미만으로, 중요 거래로 간주되지 않습니다.

BeOne Medicines (ONC) a déposé un formulaire 4 de routine indiquant que le responsable mondial de la R&D, Lai Wang, a vendu 1 028 American Depositary Shares le 23/06/2025 au prix de 260 $ chacune (environ 0,27 million de dollars) pour couvrir la retenue d'impôt liée aux RSU acquises. Après la vente, il détient encore 1 023 529 actions ordinaires directement et 731 965 indirectement via Wang Holdings LLC, soit environ 1,76 million d’actions au total. La transaction représente moins de 1 % de sa détention totale et n’est pas considérée comme significative.

BeOne Medicines (ONC) reichte ein routinemäßiges Formular 4 ein, das zeigt, dass der globale Leiter der Forschung & Entwicklung, Lai Wang, am 23.06.2025 1.028 American Depositary Shares zu je 260 USD (ca. 0,27 Millionen USD) verkauft hat, um die Steuerabzüge im Zusammenhang mit erworbenen RSUs zu decken. Nach dem Verkauf hält er noch 1.023.529 Stammaktien direkt und 731.965 indirekt über Wang Holdings LLC – zusammen etwa 1,76 Millionen Aktien. Die Transaktion macht weniger als 1 % seines Gesamtbesitzes aus und wird nicht als wesentlich betrachtet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Wang Lai

(Last) (First) (Middle)
C/O BEONE MEDICINES I GMBH
AESCHENGRABEN 27, 21ST FLOOR

(Street)
BASEL V8 4051

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BeOne Medicines Ltd. [ ONC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Global Head of R&D
3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares 1,023,529 D
Ordinary Shares 731,965 I See Footnote(1)
RMB Shares(2) 0(3)(4) I See Footnote(4)
American Depositary Shares(5) 06/23/2025 S(6) 1,028 D $260 0 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. These securities are held by Wang Holdings LLC, the limited liability company interests of which are owned by the Reporting Person, his spouse and a trust created by the Reporting Person for the benefit of his spouse and children, for which the Reporting Person disclaims beneficial ownership.
2. The term "RMB Shares" is used herein to represent the ordinary shares, par value $0.0001 per share, of the Issuer, issued directly by the Issuer in the Issuer's initial public offering on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange (the "STAR Offering"), to permitted investors in Renminbi ("RMB") within the People's Republic of China ("PRC") in accordance with the rules of the STAR Market.
3. The Issuer established an employee participation program ("RMB Shares Employee Participation Plan"), which allows certain executive officers and qualified employees of the Issuer's subsidiaries in the PRC to indirectly participate in the STAR Offering and purchase certain RMB Shares from the Issuer through an asset management plan administrated by China International Capital Corporation Limited in a transaction that is exempt under Rule 16b-3. The RMB Share Employee Participation Plan purchased an aggregate of 2,069,546 RMB Shares directly from the Issuer in the STAR Offering at the initial public offering price of RMB192.6 per RMB Share (or $30.1295 based on an assumed exchange rate of $1.00 = RMB6.3924).
4. The Reporting Person, as an individual participant in the RMB Shares Employee Participation Plan, has contributed RMB10 million to the RMB Shares Employee Participation Plan. The Reporting Person may be deemed to have indirect economic interest in an indeterminable portion of the RMB Shares held by the RMB Shares Employee Participation Plan but does not have voting or dispositive power over any of such shares. The Reporting Person disclaims Section 16 beneficial ownership of the RMB Shares held by the RMB Shares Employee Participation Plan, except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such RMB Shares for Section 16 or any other purpose.
5. Each American Depositary Share represents 13 Ordinary Shares.
6. The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
Remarks:
/s/ Qing Nian, as Attorney-in-Fact 06/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many ADS did ONC's insider sell on June 23 2025?

He sold 1,028 American Depositary Shares, equal to 13,364 ordinary shares.

What was the sale price per ADS for BeOne Medicines' insider trade?

The reported sale price was $260 per ADS.

Why did Lai Wang sell shares according to the Form 4 filing?

The sale was executed to satisfy mandatory tax withholding on a vesting restricted share unit award.

How many ordinary shares does the insider still own after the sale?

He continues to hold 1,023,529 shares directly and 731,965 indirectly, totaling about 1.76 million shares.
Beigene Ltd

NASDAQ:ONC

ONC Rankings

ONC Latest News

ONC Latest SEC Filings

ONC Stock Data

27.87B
88.96M
19.24%
42.54%
2.36%
Biotechnology
Pharmaceutical Preparations
Link
Cayman Islands
GRAND CAYMAN